Helus Pharma CEO to Present at Canaccord Genuity Growth Conference

Helus Pharma (Nasdaq: HELP) said CEO Michael Halstead will take part in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston. The session is set for Wednesday, Aug. 12 at 12 p.m. EDT.

The company is a clinical-stage pharmaceutical firm focused on novel serotonergic agonists, or NSAs, for mental health conditions. Its lead candidate, HLP003, is in Phase 3 testing for major depressive disorder as an adjunctive treatment. The FDA granted HLP003 Breakthrough Therapy Designation. A second drug, HLP004, is in Phase 2 for generalized anxiety disorder.

Halstead's appearance comes as the company works to advance its pipeline through late-stage trials. The webcast will be available live and on replay through the company's investor relations page.